In an interview with PharmaShots, Dr. Lotus Mallbris, M.D., Ph.D., Vice President of Immunology Development at Lilly shared her views on the abstracts demonstrating data on the use of Taltz and Olumiant in rheumatic […]readmore
Tags : Olumiant
Shots: The new analyses of the P-III BREEZE-AD5 trial and an extended safety analysis across multiple trials for Olumiant (2mg, qd) vs PBO in patients with AD showed improvements in […]readmore
Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012 The Breakthrough Designation is granted to […]readmore
Lilly and Incyte’s Olumiant (baricitinib) Reports Additional Data Demonstrating Reduction
Shots: The companies shared the additional efficacy and safety data of the ACTT-2 study demonstrating baricitinib + remdesivir reduced time to recovery and improved clinical outcomes for patients with COVID-19 […]readmore
Shots: The positive opinion is based on P-III BREEZE-AD program including BREEZE-AD1 & BREEZE-AD2 studies assessing baricitinib as monothx. in mod. to sev. AD patients The CHMP’s recommendation also involves […]readmore
Shots: Eli Lilly and Incyte report the initial result of NIAID sponsored ACTT-2 study assessing the efficacy and safety of Olumiant (baricitinib, 4mg) + Veklury (remdesivir) vs Veklury as monothx. […]readmore
Shots: Lilly to present results from a long-term study that evaluated the efficacy of Olumiant (4mg, qd) in patients with mod. to sev. RA for 3yrs. of treatment. The study […]readmore
Shots: The FDA’s BT designation is based on P-II results of P-II/III BRAVE-AA1 study assessing baricitinib vs PBO in patients with AA The P-II portion of the BRAVE-AA1 study demonstrated […]readmore
Shots: The P-III BREEZE-AD7 study involves assessing of Olumiant (2mg, 4mg) + SOC topical corticosteroids vs PBO in patients with moderate to severe atopic dermatitis for 16wks. The P-II BREEZE-AD […]readmore
Shots: The two P-III study BREEZE-AD1 and BREEZE-AD2 involves assessing of baricitinib vs PBO in patients with moderate-to-severe AD The two P-III study resulted in meeting 1EPs @16 wks. with […]readmore